The_DT
predominant_JJ
E2F_NN
complex_NN
in_IN
human_JJ
primary_JJ
hemopoietic_JJ
cells_NNS
and_CC
in_IN
AML_NN
blasts_NNS
contains_VBZ
E2F-4_NN
,_,
DP-1_NN
and_CC
p130_NN
._.

The_DT
E2F_NN
family_NN
of_IN
transcription_NN
factors_NNS
are_VBP
thought_VBN
to_TO
play_VB
an_DT
important_JJ
role_NN
in_IN
the_DT
control_NN
of_IN
cell_NN
cycle_NN
progression_NN
._.

There_EX
is_VBZ
now_RB
also_RB
increasing_VBG
evidence_NN
that_IN
some_DT
family_NN
members_NNS
may_MD
act_VB
as_IN
oncogenes_NNS
or_CC
tumor_NN
suppressor_NN
genes_NNS
._.

The_DT
characterization_NN
of_IN
these_DT
proteins_NNS
in_IN
human_JJ
primary_JJ
hemopoietic_JJ
cells_NNS
and_CC
acute_JJ
myeloid_JJ
leukemia_NN
-LRB-_-LRB-
AML_NN
-RRB-_-RRB-
blasts_NNS
may_MD
thus_RB
give_VB
an_DT
insight_NN
to_TO
the_DT
molecular_JJ
mechanisms_NNS
governing_VBG
proliferation_NN
and_CC
leukemogenesis_NN
in_IN
these_DT
cells_NNS
._.

Therefore_RB
we_PRP
analyzed_VBD
the_DT
expression_NN
of_IN
E2F-DNA_NN
binding_NN
activity_NN
and_CC
the_DT
constituent_JJ
proteins_NNS
found_VBN
in_IN
the_DT
complexes_NNS
in_IN
human_JJ
primary_JJ
hemopoietic_JJ
cells_NNS
of_IN
various_JJ
lineages_NNS
._.

We_PRP
also_RB
studied_VBD
blasts_NNS
from_IN
18_CD
patients_NNS
with_IN
acute_JJ
myeloid_JJ
leukemia_NN
-LRB-_-LRB-
AML_NN
-RRB-_-RRB-
._.

On_IN
electromobility_NN
shift_NN
assays_NNS
-LRB-_-LRB-
EMSA_NN
-RRB-_-RRB-
a_DT
single_JJ
E2F-DNA_NN
binding_NN
complex_NN
was_VBD
detected_VBN
in_IN
T_NN
cells_NNS
,_,
B_NN
cells_NNS
and_CC
monocytes_NNS
which_WDT
was_VBD
shown_VBN
to_TO
contain_VB
E2F-4_NN
,_,
DP-1_NN
and_CC
p130_NN
,_,
indicating_VBG
that_IN
all_DT
quiescent_JJ
hemopoietic_JJ
cells_NNS
have_VBP
the_DT
same_JJ
complex_NN
._.

Examination_NN
of_IN
18_CD
AML_NN
samples_NNS
by_IN
EMSA_NN
revealed_VBD
the_DT
presence_NN
of_IN
E2F_NN
binding_NN
and_CC
no_DT
gross_JJ
abnormalities_NNS
were_VBD
detected_VBN
._.

An_DT
E2F-4_NN
\/_:
p130_NN
complex_NN
was_VBD
detected_VBN
in_IN
representative_JJ
samples_NNS
of_IN
all_DT
FAB_NN
types_NNS
analyzed_VBN
._.

Thus_RB
abnormalities_NNS
of_IN
E2F_NN
function_NN
are_VBP
unlikely_JJ
to_TO
play_VB
a_DT
primary_JJ
pathogenic_JJ
role_NN
in_IN
AML_NN
._.

